Financial News

Recent Quotes
My Watchlist
Indicators
Motherlode Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aimmune Therap (NQ: AIMT )

34.49 USD UNCHANGED
Last Price Updated: 7:11 PM EDT, Oct 12, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Stories about Aimmune Therap

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
UPDATE 2-Aimmune sees coronavirus slowing down marketing of peanut allergy therapy
Aimmune Therapeutics Inc on Monday warned of a slow launch of its peanut allergy therapy, as its marketing plans take a hit from U.S. authorities' recommendation of social distancing to contain the... 
Tags companyNews
From Reuters: Company News
UPDATE 1-Aimmune sees slowdown in launch of peanut allergy therapy due to coronavirus
Aimmune Therapeutics Inc said on Monday the launch of its peanut allergy therapy may be slowed by the spread of coronavirus in the United States. 
Tags companyNews
From Reuters: Company News
Aimmune says peanut allergy therapy launch may be slowed down by coronavirus
Aimmune Therapeutics Inc on Monday said the launch of its peanut allergy therapy may be slowed down by the spread of the coronavirus in the United States. 
Tags companyNews
From Reuters: Company News
Stocks That Hit 52-Week Lows On Monday
On Monday, 2568 stocks hit new 52-week lows. Areas of Significance: Amazon.com(NASDAQ: AMZN)is the largest company ... 
Tags FOXF TBBK BIT
From Benzinga
Stocks That Hit 52-Week Lows On Friday
Friday morning, 344 companies set new 52-week lows. Interesting Highlights: The largest company by market cap to set a new ... 
Tags FNKO SANM QIWI
From Benzinga
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning session, various companies made new 52-week lows. Intriguing Points: Facebook(NASDAQ: ... 
Tags MHK FRME PQG
From Benzinga
Aimmune Therapeu Has Returned 30.6% Since SmarTrend Recommendation (AIMT)
SmarTrend identified a Downtrend for Aimmune Therapeu (NASDAQ:AIMT) on February 6th, 2020 at $29.72. In approximately 1 month, Aimmune Therapeu has returned 30.64% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
Analysts Anticipate ESGV Will Reach $63
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Why Aimmune Therapeutics Shares Fell 23.3% in February
A risk management process slowed the launch of Aimmune’s first product. 
Tags DBVT Market News AIMT
From Motley Fool
Aimmune's Launch of Peanut Allergy Drug Will Take Time
A month after the drug's approval, Aimmune is still working on getting it to patients. 
Tags AIMT Market News
From Motley Fool
Aimmune Therapeutics Inc (AIMT) Q4 2019 Earnings Call Transcript
AIMT earnings call for the period ending December 31, 2019. 
Tags Market News AIMT
From Motley Fool
The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that ... 
Tags ABMD VIVO ALIM
From Benzinga
The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace
Biotech stocks turned in a lackadaisical performance last week amid earnings releases by smid-cap stocks, a few clinical readouts and ... 
Tags BDTX MMSI ALLO
From Benzinga
Aimmune Therapeutics Just Made History: Is It a Buy?
The food allergy specialist just landed its first approval. 
Tags Market News DBVT AIMT
From Motley Fool
Aimmune Analyst Says Palforzia Launch Funding Secured With Nestle's $200M Investment
Aimmune Therapeutics Inc (NASDAQ: AIMT) recently received FDAapproval for its peanut allergy drug Palforzia. The Aimmune ... 
Tags NSRGY Benzinga XNCR
From Benzinga
UPDATE 3-Nestle invests $200 mln more in Aimmune after peanut allergy drug approval
Aimmune Therapeutics Inc said on Wednesday the health science arm of Nestle SA will invest an additional $200 million, days after the drugmaker won U.S. approval for its peanut allergy therapy, touted... 
Tags companyNews
From Reuters: Company News
68 Stocks Moving In Wednesday's Mid-Day Session
Gainers Myomo, Inc. (NYSE: MYO) shares climbed 118% to $28.31. Myomo shares surged around 115% on Tuesday after the company's ... 
Tags Semiconductors UNM CPRI
From Benzinga
Full Steam Ahead For Aimmune Therapeutics and the World's First Peanut Allergy Therapy
Another $200 million investment from Nestle will turbocharge Palforzia's commercial launch. 
Tags AIMT NSRGY Market News
From Motley Fool
UPDATE 2-Nestle invests $200 mln more in Aimmune after peanut allergy drug approval
Aimmune Therapeutics Inc said on Wednesday the health science arm of Nestle SA will invest an additional $200 million, days after the drugmaker won U.S. approval for its peanut allergy therapy, touted... 
Tags companyNews
From Reuters: Company News
UPDATE 1-Nestle invests $200 mln more in Aimmune after peanut allergy drug approval
Aimmune Therapeutics Inc said on Wednesday the health science arm of Nestle SA will invest an additional $200 million in the drugmaker, bringing the Swiss company's total investment to $473 million. 
Tags companyNews
From Reuters: Company News
Nestle raises stake in Aimmune after peanut allergy therapy approval
Aimmune Therapeutics Inc said on Wednesday the health science arm of Nestle SA will invest an additional $200 million in the drugmaker, bringing the Swiss company's total investment to $473 million. 
Tags companyNews
From Reuters: Company News
Analysts Forecast 10% Gains Ahead For ESML
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
What Aimmune's Peanut Allergy Drug Approval Means for the Rest of the Pipeline
The FDA’s approval sets the company off on the right path as it advances in the treatment of food allergies. 
Tags DBVT Market News AIMT
From Motley Fool
68 Biggest Movers From Yesterday
Gainers Myomo Inc (NYSE: MYO) shares climbed 114.7% to close at $12.99 on Tuesday after the company's MyoPro was approved for ... 
Tags RMTI DGLY NIO
From Benzinga
85 Biggest Movers From Yesterday
Gainers China Pharma Holdings, Inc. (NYSE: CPHI) shares climbed 96.5% to close at $0.92 on Monday after gaining 11.50% on ... 
Tags GRAM TAL VIE
From Benzinga
FDA Approves First Drug for Peanut Allergy
The first approved drug for any food allergy may be the first of several from Aimmune Therapeutics. 
Tags Market News AIMT
From Motley Fool
61 Stocks Moving In Monday's Mid-Day Session
Gainers China Pharma Holdings, Inc. (NYSE: CPHI) shares jumped 88% to $0.88 after gaining 11.50% on Friday. Artelo Biosciences, ... 
Tags PCG EROS CTIC
From Benzinga
Aimmune Analysts Bullish On Strong Uptake Of Peanut Allergy Drug Palforzia
Aimmune Therapeutics Inc (NASDAQ: AIMT) announced late Friday that it received FDA approvalfor Palforzia, its oral immunotherapy ... 
Tags Analyst Ratings Reiteration Kennen MacKay
From Benzinga
10 Biggest Price Target Changes For Monday
SunTrust Robinson Humphrey boosted Biogen Inc (NASDAQ: BIIB) price target from $337 to $360. Biogen closed at $268.85 on ... 
Tags MNST Benzinga ULTA
From Benzinga
Aimmune Shares Can Trade Into The $60 Range, Says Piper Sandler
Piper Sandler analyst Christopher Raymond says he continues to believe shares of Aimmune Therapeutics can trade into the $60 range following Friday's FDA approval of peanut allergy treatment... 
Tags Stocks / Equities Pharma/Biotech
From Blogs - TalkMarkets
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback